Matthew Wakefield

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley, Cordelia D McGehee, Cassandra J Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Anna DeFazio, et al.

Journal article  |  2021  |  CANCER RESEARCH

In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defectiv..

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, Cristina Correia, Taylor M Weiskittel, Rebecca L Kelly, Annapoorna Venkatachalam, Xiaonan Hou, Nicholas M Pathoulas, X Wei Meng, Olga Kondrashova, Marc R Radke, Paula A Schneider, Karen S Flatten, Kevin L Peterson, Marc A Becker, Ee Ming Wong, Melissa S Southey, Alexander Dobrovic, Kevin K Lin, et al.

Journal article  |  2021  |  NAR Cancer

Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that re..

Abstract 1074: Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  Experimental and Molecular Therapeutics

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Ksenija Nesic, Cassandra J Vandenberg, Olga Kondrashova, John J Krais, Neil Johnson, Elizabeth M Swisher, Matthew J Wakefield, Clare L Scott

Conference Proceedings  |  2021  |  Molecular and Cellular Biology/Genetics

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C Chueh, Judy Doherty, Francois Vaillant, Gwo-Yaw Ho, Matthew J Wakefield, Clare E Weeden, Alvin Kamili, Jayne Murray, Sela T Po'uha, Janet Weinstock, Serena R Kane, Maree C Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J Kershaw, et al.

Journal article  |  2021  |  CELL DEATH & DISEASE

Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limita..

Building the infrastructure required to research novel therapies for 35% of women with endometrial cancer who have rare subtypes.

Clare L Scott, Ratana Lim, Amandine Carmagnac, Cassandra Vandenberg, Gayanie Ratnayake, Genevieve Dall, Joshua Tram, Justin Bedo, Jocelyn Penington, Joep Vissers, Sean Grimmond, Matthew Wakefield, Anthony Papenfuss, Holly Barker

Conference Proceedings  |  2021  |  CLINICAL CANCER RESEARCH

Abstract PO037: Identifying effective combinations of targeted therapies, using novel pre-clinical models, to improve treatment options for high-grade serous endometrial cancer

Holly E Barker, Ratana Lim, Amandine Carmagnac, Cassandra Vandenberg, Gayanie Ratnayake, Genevieve Dall, Briony Milesi, Angela Komiti, Emily O'Grady, Joshua Tram, Kym Pham Stewart, Justin Bedo, Jocelyn Penington, Joep Vissers, Sean Grimmond, Matthew Wakefield, Tony Papenfuss, Clare Scott

Conference Proceedings  |  2021  |  Targeted Therapeutics

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Journal article  |  2021  |  MODERN PATHOLOGY

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis

Felix KF Kommoss, Dane Cheasley, Matthew J Wakefield, Clare L Scott, Ian G Campbell, C Blake Gilks, Kylie Gorringe

Journal article  |  2020  |  HISTOPATHOLOGY

Recently, genetic analyses of primary mucinous ovarian tumours (MOT) have considerably enhanced our understanding of the biology o..

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response.

Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I Harrell, Giada V Zapparoli, Ashan Musafer, Ming E Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H Kaufmann, Clare L Scott

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH